HAS1 Inhibitors
HAS1, a key enzyme in hyaluronan synthesis, is targeted by a variety of inhibitors influencing specific cellular pathways. 4-Methylumbelliferone directly inhibits HAS1 by competitively binding to its substrate binding site, preventing hyaluronan synthesis. Suramin disrupts TGF-β signaling, indirectly inhibiting HAS1 by decreasing its transcription. LY294002 and Wortmannin, both PI3K inhibitors, indirectly inhibit HAS1 by disrupting the PI3K/Akt signaling pathway, reducing Akt phosphorylation and subsequently decreasing HAS1 activity. SB431542, a TGF-β receptor inhibitor, indirectly inhibits HAS1 by blocking TGF-β signaling, leading to decreased HAS1 transcription.
XAV939, a tankyrase inhibitor, indirectly inhibits HAS1 by modulating the Wnt/β-catenin pathway, impacting HAS1 activity. Celecoxib, a COX-2 inhibitor, indirectly inhibits HAS1 by influencing the prostaglandin pathway, leading to reduced HAS1 transcription. Curcumin disrupts NF-κB signaling, indirectly inhibiting HAS1 by decreasing its transcription. GDC-0879, a RAF inhibitor, indirectly inhibits HAS1 by affecting the MAPK/ERK signaling pathway, reducing ERK phosphorylation and subsequently decreasing HAS1 activity. Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits HAS1 by affecting Src family kinases, leading to decreased HAS1 phosphorylation. CAY10585, a dual inhibitor of PI3K and mTOR, indirectly inhibits HAS1 by disrupting the PI3K/mTOR signaling pathway, decreasing Akt phosphorylation and impacting HAS1 activity. PF-543, a selective SphK1 inhibitor, indirectly inhibits HAS1 by affecting the SphK1/S1P signaling pathway, leading to decreased S1P levels and subsequently reducing HAS1 activity. This comprehensive understanding of HAS1 inhibitors provides insights into potential strategies for modulating hyaluronan synthesis and contributes to unraveling the complexity of cellular processes regulated by HAS1-mediated hyaluronan production.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
4-Methylumbelliferone | 90-33-5 | sc-206910 sc-206910A sc-206910B sc-206910C sc-206910D | 25 g 100 g 250 g 1 kg 2.5 kg | $34.00 $55.00 $138.00 $423.00 $954.00 | 2 | |
4-Methylumbelliferone, an inhibitor of hyaluronan synthases (HAS), directly inhibits HAS1 by interfering with its enzymatic activity. It competitively inhibits the substrate binding site of HAS1, preventing the synthesis of hyaluronan, a major product of HAS enzymes. This leads to reduced hyaluronan production and consequently inhibits the cellular functions associated with elevated hyaluronan levels driven by HAS1 activity. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin, a polyanionic compound, indirectly inhibits HAS1 by disrupting the TGF-β signaling pathway. HAS1 expression is regulated by TGF-β, and suramin inhibits TGF-β activation, leading to decreased HAS1 transcription. This indirect inhibition results in reduced hyaluronan synthesis by HAS1, impacting cellular processes associated with hyaluronan-dependent signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a specific PI3K inhibitor, indirectly inhibits HAS1 by disrupting the PI3K/Akt signaling pathway. HAS1 activity is regulated by the PI3K/Akt pathway, and LY294002 inhibits PI3K, leading to reduced Akt phosphorylation. This indirect inhibition results in decreased HAS1 activity and subsequent hyaluronan synthesis, affecting cellular processes associated with hyaluronan-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a fungal metabolite and PI3K inhibitor, indirectly inhibits HAS1 by disrupting the PI3K/Akt signaling pathway. HAS1 activity is regulated by the PI3K/Akt pathway, and wortmannin inhibits PI3K, leading to reduced Akt phosphorylation. This indirect inhibition results in decreased HAS1 activity and subsequent hyaluronan synthesis, impacting cellular processes associated with hyaluronan-mediated signaling. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly inhibits HAS1 by blocking TGF-β signaling. HAS1 expression is regulated by TGF-β, and SB431542 prevents TGF-β-induced activation of its receptors, leading to decreased HAS1 transcription. This indirect inhibition results in reduced hyaluronan synthesis by HAS1, impacting cellular processes associated with hyaluronan-dependent signaling. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV939, a tankyrase inhibitor, indirectly inhibits HAS1 by modulating the Wnt/β-catenin signaling pathway. HAS1 activity is influenced by Wnt signaling, and XAV939 inhibits tankyrase, leading to stabilization of axin and subsequent inhibition of β-catenin. This indirect inhibition results in decreased HAS1 activity and hyaluronan synthesis, affecting cellular processes associated with Wnt-mediated regulation of hyaluronan production. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin, a natural compound, indirectly inhibits HAS1 by disrupting the NF-κB signaling pathway. HAS1 expression is regulated by NF-κB, and curcumin inhibits NF-κB activation, leading to decreased HAS1 transcription. This indirect inhibition results in reduced hyaluronan synthesis by HAS1, impacting cellular processes associated with NF-κB-mediated regulation of hyaluronan production. | ||||||
GDC-0879 | 905281-76-7 | sc-364497 | 5 mg | $225.00 | ||
GDC-0879, a selective RAF inhibitor, indirectly inhibits HAS1 by affecting the MAPK/ERK signaling pathway. HAS1 activity is influenced by MAPK/ERK signaling, and GDC-0879 inhibits RAF, leading to decreased ERK phosphorylation. This indirect inhibition results in reduced HAS1 activity and hyaluronan synthesis, impacting cellular processes associated with MAPK/ERK-mediated regulation of hyaluronan production. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits HAS1 by affecting Src family kinases. HAS1 activity is regulated by Src family kinases, and dasatinib inhibits their activity, leading to decreased HAS1 phosphorylation. This indirect inhibition results in reduced HAS1 activity and hyaluronan synthesis, impacting cellular processes associated with Src family kinase-mediated regulation of hyaluronan production. | ||||||
Hypoxia inducible factor-1α inhibitor | 934593-90-5 | sc-205346 sc-205346A sc-205346B sc-205346C | 1 mg 5 mg 10 mg 25 mg | $32.00 $112.00 $190.00 $403.00 | 40 | |
Also called CAY10585, this compound is a dual inhibitor of PI3K and mTOR, indirectly inhibits HAS1 by disrupting the PI3K/mTOR signaling pathway. HAS1 activity is regulated by PI3K/mTOR signaling, and CAY10585 inhibits both PI3K and mTOR, leading to decreased Akt phosphorylation. This indirect inhibition results in reduced HAS1 activity and hyaluronan synthesis, impacting cellular processes associated with PI3K/mTOR-mediated regulation of hyaluronan production. | ||||||